Skip to main content
AsthmaHealthy volunteersBiologicalPhase 2

What this study is

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

What's being tested

  • Research Grade RG-RV

    Intervention · BIOLOGICAL

    Exploration of the effects of RV inoculation on human airway mucosal programming in vivo

Study details

Official title
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING
Sponsor
The University of Texas Medical Branch, Galveston
Conditions
Asthma · Allergic Rhinitis · Cat Allergy · Healthy
Enrolling
75 people
Starts
2023-04-27
Est. completion
2027-05-01
Design
Open-label, non-randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗